Jazz Pharmaceuticals PLC

자세한 내용은 Jazz Pharmaceuticals PLC 회사

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Jazz Pharmaceuticals PLC 정보



종목 코드 JAZZ

회사 이름Jazz Pharmaceuticals PLC

상장일Jan 18, 2012

CEOMs. Renee D. Gala

직원 수2800

유형Ordinary Share

회계 연도 종료Jan 18

주소Fifth Floor, Waterloo Exchange

도시DUBLIN

증권 거래소NASDAQ Global Select Consolidated

국가Ireland

우편 번호- -

전화35316347800

웹사이트https://www.jazzpharma.com/

종목 코드 JAZZ

상장일Jan 18, 2012

CEOMs. Renee D. Gala

Jazz Pharmaceuticals PLC의 회사 임원진



이름

이름/직위

직위

주식 보유

변동

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

307.81K

-1.76%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+13.93%

Ms. Anne O'Riordan

Independent Director

12.77K

+15.38%

Mr. Rick E. Winningham

Lead Independent Director

10.66K

+19.00%

이름

이름/직위

직위

주식 보유

변동

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

307.81K

-1.76%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.20K

+64.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

29.39K

+6.15%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

수익 분석

통화: USD마지막 업데이트: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

기타

149.32M

14.28%

지역별USD

이름

수익

비율

United States

936.28M

89.54%

Europe

82.76M

7.91%

All Others

26.67M

2.55%

사업별

지역별

사업별USD

이름

수익

비율

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

기타

149.32M

14.28%

주식 보유 통계

마지막 업데이트: Thu, Oct 16

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

기타

68.80%

주주

비율

The Vanguard Group, Inc.

10.00%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.21%

Capital World Investors

4.19%

Dimensional Fund Advisors, L.P.

4.18%

기타

68.80%

주주 유형

주주

비율

Investment Advisor

52.52%

Investment Advisor/Hedge Fund

34.31%

Hedge Fund

8.96%

Research Firm

3.43%

Individual Investor

3.07%

Pension Fund

2.79%

Venture Capital

1.89%

Bank and Trust

0.96%

Sovereign Wealth Fund

0.12%

기관 주식 보유



마지막 업데이트: Wed, Oct 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q3

1191

64.20M

105.84%

-4.58M

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

주주 활동



이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

6.07M

10%

+73.43K

+1.22%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.22M

8.61%

+11.23K

+0.22%

Jun 30, 2025

LSV Asset Management

2.55M

4.21%

+87.58K

+3.55%

Jun 30, 2025

Capital World Investors

2.54M

4.19%

+616.73K

+31.99%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.54M

4.18%

+209.41K

+8.99%

Jun 30, 2025

State Street Investment Management (US)

1.94M

3.19%

-31.20K

-1.59%

Jun 30, 2025

EcoR1 Capital, LLC

1.71M

2.81%

--

Jun 30, 2025

Fuller & Thaler Asset Management Inc.

1.63M

2.69%

+297.95K

+22.39%

Jun 30, 2025

JP Morgan Asset Management

1.55M

2.55%

+46.92K

+3.12%

Jun 30, 2025

Columbia Threadneedle Investments (US)

1.54M

2.54%

+186.67K

+13.80%

Jun 30, 2025

주식 배당금



지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

데이터 없음

주식 분할



날짜

유형

비율

데이터 없음

날짜

유형

비율

데이터 없음

자세한 내용은 Jazz Pharmaceuticals PLC 회사

Jazz Pharmaceuticals PLC 정보

Jazz Pharmaceuticals PLC의 회사 임원진

수익 분석

주식 보유 통계

기관 주식 보유

주주 활동

관련 ETF

주식 배당금

주식 분할